Follow
Qing Xi Ooi
Qing Xi Ooi
MIDD Consultant, Pharmetheus AB
Verified email at pharmetheus.com
Title
Cited by
Cited by
Year
A joint model for vitamin K-dependent clotting factors and anticoagulation proteins
QX Ooi, DFB Wright, RC Tait, GK Isbister, SB Duffull
Clinical pharmacokinetics 56 (12), 1555-1566, 2017
132017
Evaluation of assumptions underpinning pharmacometric models
QX Ooi, DFB Wright, GK Isbister, SB Duffull
The AAPS journal 21 (5), 1-11, 2019
52019
On the preferred structure of dicoumarol and implications for enzyme binding: a quantum chemical analysis
BM Hussain, K Hassam, QX Ooi, RA Bryce
Chemical Physics Letters 602, 45-51, 2014
42014
A factor VII-based method for the prediction of anticoagulant response to warfarin
QX Ooi, DFB Wright, GK Isbister, SB Duffull
Scientific reports 8 (1), 1-12, 2018
32018
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
Y Tomita, E Hansson, F Mazuir, GJ Wellhagen, QX Ooi, E Mezzalana, ...
Clinical and translational science 15 (4), 1014-1026, 2022
22022
Kinetic‐pharmacodynamic model for drugs with non‐linear elimination: Parameterisation matters
QX Ooi, C Hasegawa, SB Duffull, DFB Wright
British Journal of Clinical Pharmacology 86 (2), 196, 2020
22020
Application of pharmacometric methods to understand warfarin dose response
QX Ooi
University of Otago, 2018
2018
Population Approach Group Europe Population Approach Group Europe
QX Ooi
Population pharmacokinetic modeling and simulation of imeglimin in type 2 diabetes patients to support dose recommendations to patients with renal impairment
E Mezzalana, Y Tomita, E Hansson, F Mazuir, G Wellhagen, QX Ooi, ...
Age 62 (32), 83, 0
The system can't perform the operation now. Try again later.
Articles 1–9